• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Estrogen Receptor-Targeted and Progesterone Receptor-Targeted PET for Patients with Breast Cancer
PET Clin. 2023 Jun 1:S1556-8598(23)00050-0. doi: 10.1016/j.cpet.2023.04.008. Online ahead of print.ABSTRACTEstrogen receptor (ER)-targeted imaging with 16α-18F-fluoro-17β-fluoroestradiol (18F-FES) has multiple proven clinical applications for patients with ER-positive breast cancer, including helping to select optimal patients for endocrine therapies, assessing ER status in lesions that are difficult to biopsy, and evaluating lesions with inconclusive results on other imaging tests. This has led to US Food and Drug Administration approval of 18F-FES PET for patients with ER-positive breast cancer. Newer progesterone rece...
Source: Clinical Breast Cancer - June 3, 2023 Category: Cancer & Oncology Authors: Gary A Ulaner Amy M Fowler Amy S Clark Hannah Linden Source Type: research

Ki67 in Breast Cancer Assay: An Ad Hoc Testing Recommendation from the Canadian Association of Pathologists Task Force
Curr Oncol. 2023 Mar 6;30(3):3079-3090. doi: 10.3390/curroncol30030233.ABSTRACTKi67, a marker of cellular proliferation, is commonly assessed in surgical pathology laboratories. In breast cancer, Ki67 is an established prognostic factor with higher levels associated with worse long-term survival. However, Ki67 IHC is considered of limited clinical use in breast cancer management largely due to issues related to standardization and reproducibility of scoring across laboratories. Recently, both the American Food and Drug Administration (FDA) and Health Canada have approved the use of abemaciclib (CDK4/6 inhibitor) for patien...
Source: Cancer Control - March 28, 2023 Category: Cancer & Oncology Authors: Hala Faragalla Anna Plotkin Penny Barnes Fang-I Lu Zuzana Kos Anna Marie Mulligan Anita Bane Sharon Nofech Mozes Source Type: research

A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ER α degradation and the autophagy-lysosome pathway
Bioorg Med Chem. 2023 Mar 7;82:117235. doi: 10.1016/j.bmc.2023.117235. Online ahead of print.ABSTRACTBreast cancer (BC), a well-known estrogen-dependent cancer, is the most common cancer among women and the leading cause of cancer deaths. One of the most important therapeutic approaches for BC is endocrine therapy targeting estrogen receptor alpha (ERα) and thus blocking the estrogen receptor signaling pathway. Drugs, such as tamoxifen or fulvestrant, are developed based on this theory and have benefited numerous patients with BC for many years. However, many patients with advanced BC, such as tamoxifen-resistant BC, cann...
Source: Bioorganic and Medicinal Chemistry - March 11, 2023 Category: Chemistry Authors: Jiawei Zhou Rong Shen Jing Liu Xiangping Deng Lilan Xin Hai-Bing Zhou Jian Huang Source Type: research

Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer
Zhonghua Zhong Liu Za Zhi. 2022 Jul 23;44(7):673-692. doi: 10.3760/cma.j.cn112152-20220412-00251.ABSTRACTPhosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway (PAM pathway) plays an important role in the development of breast cancer and are closely associated with the resistance to endocrine therapy in advanced breast cancer. Therefore, anti-cancer treatment targeting key molecules in this signaling pathway has become research hot-spot in recent years. Randomized clinical trials have demonstrated that PI3K/AKT/mTOR inhibitors bring significant clinical benefit to pat...
Source: Cancer Control - July 26, 2022 Category: Cancer & Oncology Authors: China Anti-cancer Association Tumor Drug Clinical Research Committee; Breast Cancer Expert Committee, National Tumor Quality Control Center; Tumor Pathology Committee of China Anti-cancer Association; Boao Institute of Oncology Innovation Source Type: research